Insight Surgery, a UK healthtech startup, has raised $2.5 million to expand its personalised surgery platform across the US. The company helps hospitals perform orthopaedic procedures faster, safer, and with greater precision—while cutting costs.
In orthopaedic surgery, every minute matters. Delays can lead to complications, longer recoveries, and higher expenses. Nearly 1 in 7 patients is readmitted within a month of major surgery. Even one extra hour in the operating room can add thousands to the bill.
Insight Surgery wants to change that.
Its platform transforms medical scans into custom 3D-printed surgical guides. These patient-specific tools help surgeons work more accurately, reduce time in the OR, and lower the risk of readmission. Clinical data shows the guides save an average of 23 minutes per procedure. That means fewer complications—and major savings.
Speed, Precision, and a Growing US Footprint
Nodenza Venture Partners led the funding, backing Insight just months after the company earned FDA clearance. Its guides are built using next-generation materials like LaserForm Ti and DuraForm ProX PA. These materials are up to 20 times stronger and 70% thinner than conventional ones, making procedures smoother and more efficient.
The company’s EmbedMed platform sets it apart. It lets surgeons simulate procedures and receive either digital plans or physical guides—typically within 10 days. That’s far faster than competitors, whose long lead times can delay care.
CEO Henry Pinchbeck and co-founder Peter Tofield launched the company after working on medical tech spinouts in the UK. Their goal? To make advanced surgical planning easy to use and widely accessible. Today, their ISO 13485-certified, FDA-registered facility in Houston produces all surgical guides. Being located at Texas Medical Center—the world’s largest healthcare hub—allows fast feedback and close collaboration with top surgeons.
Since launching in the US in 2023, Insight has partnered with Ricoh USA and top hospitals, including the Hospital for Special Surgery in New York and University Hospitals of Chicago. These partnerships are key to validating the technology and driving adoption.
Leading the Personalised Surgery Revolution
The personalised surgery space is growing fast. The global market for 3D surgical guides could reach $9.5 billion by 2032. Yet Insight stands out. Its fast turnaround, strong materials, and close clinical partnerships give it a real edge over companies like Materialise and 3D Systems.
Dr. Adam Levine, a leading oncology surgeon, praised the platform. He said it helps him operate with more confidence and fewer complications. That means shorter surgeries and better recoveries. For hospitals, it means fewer revisions and lower costs.
The new funding will help Insight open two manufacturing sites on the East and West Coasts. The company also plans to double its US team. This will support growth in orthopaedics and expansion into new areas like oncology and maxillofacial surgery.
Insight is also looking to the future. It’s exploring ways to use AI and machine learning in surgical planning. This could unlock even greater precision and personalisation.
Ross Morton, Managing Partner at Nodenza, sees huge potential. “Insight is delivering personalised surgery tools that work now, not years from now. They’re exactly the kind of startup we want to back.”
With strong demand, proven tech, and fresh capital, Insight Surgery is ready to reshape the future of surgery—one patient at a time.
